Clinical Trials Logo

Filter by:
NCT ID: NCT03058328 Completed - Neuroinflammation Clinical Trials

The White Blood Cell Reactivity Following Surgical Trauma and Associated Regulatory Mechanisms.

Start date: January 31, 2017
Phase:
Study type: Observational

The purpose of this study is to describe numerical and functional changes in the white blood cell efter surgical trauma. Further, observed immune cell changes correlate to heart rate variability and cognitive function will be assessed.

NCT ID: NCT03055845 Completed - Low Back Pain Clinical Trials

A Single Ascending Dose Study of Safety and Tolerability of STA363 Compared to Placebo in 15 Patients With Chronic Discogenic Low Back Pain

Start date: March 27, 2017
Phase: Phase 1
Study type: Interventional

A phase I, randomized, double-blinded, placebo-controlled, single ascending dose study to investigate the safety, local tolerability and transformation of nucleus pulposus following intradiscal injection of STA363 or placebo in patients with discogenic low back pain. 15 patients will participate in either of 3 dose groups, each comprising 5 patients: - Group 1: STA363 dose 1 (3 patients) or placebo (2 patients) - Group 2: STA363 dose 2 (3 patients) or placebo (2 patients) - Group 3: STA363 dose 3 (3 patients) or placebo (2 patients)

NCT ID: NCT03053440 Completed - Clinical trials for Waldenström's Macroglobulinemia

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

ASPEN
Start date: January 25, 2017
Phase: Phase 3
Study type: Interventional

This study evaluated the safety, efficacy and clinical benefit of BGB-3111 (zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.

NCT ID: NCT03053336 Completed - Clinical trials for Type 2 Diabetes Mellitus

App-technology to Increase Physical Activity Among Patients With Type 2 Diabetes

Start date: February 21, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the effect of using new app-based technology to improve self-care, compared to usual care in patients with type 2 diabetes. The hypothesis is that the intervention, i.e. using the new technology, will have a greater positive effect on physical activity levels and outcomes of HbA1c than usual care.

NCT ID: NCT03051958 Completed - Atopic Dermatitis Clinical Trials

Internet-based Mindfulness and Exposure Treatment for Atopic Dermatitis

Start date: March 29, 2017
Phase: N/A
Study type: Interventional

Atopic dermatitis (AD) is highly prevalent and leads to suffering for the individual, increased risk of depressive symptoms and anxiety, and high societal costs. A few psychological treatment have been tested for AD, but to our knowledge none of them have been built on recently developed methods for optimizing exposure treatment. In addition, access to psychological treatment is limited and there is a need for new methods that could be easily disseminated. One possible solution to this problem is to deliver psychological treatment via the Internet, which has been tested in more than 100 randomized trials with good results for other clinical disorders than AD. The aim of this study was to test the effects of Internet-delivered mindfulness and exposure treatment (I-MET) for AD in a randomized controlled trial. We hypothesized that I-MET would lead to larger reductions of AD symptoms as well as psychological symptoms compared to treatment as usual.

NCT ID: NCT03050138 Completed - Clinical trials for Postthrombotic Syndrome

Prevalence of Post-Thrombotic Syndrome in Deep-Vein Thrombosis (DVT) Patients Treated With Dabigatran

DABI-PTS
Start date: April 2016
Phase:
Study type: Observational

The primary objective in this cross-sectional study is to assess the prevalence of post-thrombotic syndrome (PTS) in the two treatment arms of the RE-COVER studies (warfarin versus dabigatran). PTS will be assessed by the recently developed Patient Reported Villalta (PRV) Score. Secondary objectives: to assess in both treatment arms the 1. Prevalence of recurrent venous thromboembolism (VTE) after the discontinuation of study treatment. 2. Prevalence of PTS determined by the standard Villalta score. 3. Health related Quality of Life (HRQoL).

NCT ID: NCT03048981 Completed - Surgery Clinical Trials

Effects of Fish Oil on Platelet Function and Coagulation

FOILP
Start date: March 1, 2017
Phase: N/A
Study type: Interventional

Many patients undergoing surgery use naturopathic drugs, including fish oil. Fish oil has been reported to increase bleeding in patients through inhibiting platelet aggregation and prolonging of clot formation time. The Swedish Medical Products Agency recommends that patients stop taking the naturopathic medicines including fish oil two weeks prior planed surgery. The aim of this study is to examine the effects of fish oil given to healthy volunteers using point of care coagulation assessment and flow dependent Cellix instrument before and after intake of fish oil.

NCT ID: NCT03047395 Completed - Psoriasis Clinical Trials

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )

LIMMITLESS
Start date: February 27, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.

NCT ID: NCT03041662 Completed - Cholangiocarcinoma Clinical Trials

Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)

PSC
Start date: October 31, 2011
Phase:
Study type: Observational

This observational study of a national cohort of 600 Swedish PSC patients include yearly MR/MRCP, biobanking of serum, plasma and blood, followup clinical data (interventions, symptoms, labs, colonoscopy). The aim is to collect a well characterized cohort of PSC patients and provide future possibilities to evaluate biomarkers for prognosis and early cancer detection.

NCT ID: NCT03039816 Completed - Allergic Rhinitis Clinical Trials

Cellulose Powder Against Grass Pollen Allergic Rhinitis

CPARGPDBPC
Start date: May 2013
Phase: Phase 2/Phase 3
Study type: Interventional

Background: A nasally applied cellulose powder is increasingly used in many countries as a remedy for allergic rhinitis. In 2009, a 4-week study in birch pollen-allergic children showed a reduction in nasal symptoms. The best effect occurred on days with lower pollen counts. The present study in grass pollen-allergic adults used the same basic design. Methods: In May 2013, a double-blind, placebo-controlled study was conducted in 108 patients with allergic rhinitis due to grass pollen (18-40 years of age). SMS on mobile phones were used as reminders of treatment and reporting of symptom scores.